Glurenorm (Gliquidone)

Glurenorm is indicated for the management of type 2 diabetes mellitus in adults. It may be used as part of a comprehensive diabetes treatment plan that includes diet, exercise, and other glucose‑lowering agents.

• Improves glycemic control in patients with insufficient response to diet and exercise alone.
• Can be combined with metformin or other oral antidiabetic drugs when monotherapy is inadequate.
• May be considered for patients who require an alternative to other sulfonylureas due to tolerability.
• Used under physician supervision to achieve target HbA1c levels.
• Suitable for patients with stable renal function when dosage is appropriately adjusted.

Glurenorm may cause a range of side effects, some of which are more frequently observed than others.

Common

• Mild hypoglycemia, especially when meals are skipped.
• Gastrointestinal discomfort such as nausea or abdominal pain.
• Headache or dizziness.
• Skin rash or mild itching.
• Weight gain due to increased insulin activity.

Serious

• Severe hypoglycemia leading to confusion, loss of consciousness, or seizures.
• Allergic reactions including swelling of the face, lips, or throat.
• Hepatotoxicity presenting as jaundice or elevated liver enzymes.
• Hematologic abnormalities such as leukopenia or thrombocytopenia.
• Pancreatitis with abdominal pain and elevated pancreatic enzymes.

Before initiating Glurenorm, certain precautions should be considered to ensure safe use.

• Assess renal and hepatic function; dose adjustments may be required in impairment.
• Monitor blood glucose regularly to detect hypoglycemia early.
• Use cautiously in elderly patients who may be more susceptible to low blood sugar.
• Evaluate for a history of cardiovascular disease, as sulfonylureas can affect cardiac outcomes.
• Avoid use during pregnancy or lactation unless clearly indicated by a healthcare professional.
• Discontinue if signs of severe allergic reaction or liver dysfunction appear.

Glurenorm can interact with several medications, influencing its efficacy or safety profile.

Avoid

• Concurrent use with other sulfonylureas or insulin, which may cause profound hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can increase gliquidone plasma levels.
• Certain non‑steroidal anti‑inflammatory drugs (NSAIDs) that may potentiate hypoglycemic effects.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Thiazide diuretics, as they can affect glucose metabolism.
• Alcohol, which may enhance the risk of hypoglycemia.
• Oral contraceptives, potentially altering glycemic control.